Comm Convo
January 2026 Comm Convo: State of the FDA One Year In
One year after the Trump administration took office and RFK Jr. was appointed U.S. Secretary of Health and Human Services, biopharma communicators face a fundamentally shifted regulatory landscape. Trusted FDA contacts have departed, workflows have changed, and the nonstop stream of updates from FDA, HHS, NIH, and CMS has left communications teams overwhelmed and uncertain about how to move forward. This candid panel brings together current and former FDA professionals to cut through the noise and provide practical insights on what’s actually changed, what the agency is prioritizing now, and how communicators can effectively rebuild relationships and navigate this new environment. Expect an honest, no-fluff conversation focused on the operational realities that impact your day-to-day work with the FDA.
Topics covered:
- Identify the most significant FDA changes over the past year and their direct impact on biopharma communications workflows.
- Navigate the current FDA landscape by understanding what the agency is prioritizing and looking for from industry communicators.
- Rebuild effective FDA relationships after widespread departures and staff changes disrupted established connections.
- Implement proactive strategies that help communications teams work more confidently and effectively with the agency moving forward.